DDInter655 DDInter1376
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Epirubicin {u} (Compound) treats {v} (Disease) ovarian cancer
Epirubicin {u} (Compound) binds {v} (Gene) YWHAG
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
Epirubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Epirubicin {u} (Compound) downregulates {v} (Gene) KPNA2
Epirubicin {u} (Compound) causes {v} (Side Effect) Haemoptysis
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Epirubicin (Compound) resembles Doxorubicin (Compound)
Epirubicin (Compound) resembles Valrubicin (Compound)
Epirubicin (Compound) treats ovarian cancer (Disease)
Epirubicin (Compound) binds YWHAG (Gene)
Epirubicin (Compound) upregulates SCPEP1 (Gene)
Epirubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Epirubicin (Compound) downregulates KPNA2 (Gene)
Epirubicin (Compound) causes Haemoptysis (Side Effect)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin